-Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), announced that it secured 145 billion KRW (approximately US$100 million) in convertible preferred stock investments. This round is led by returning investor KB Investment and includes other existing investors, IMM Investment, Woori Venture Partners and Stassets Investment. New investors include Weiss Asset Management, a Boston-based global investment firm, and Korea Investment Partners, a major institutional venture investor with a strong track record in biotech investment. Additional new investors in this round are DSC Investment, Company K Partners, AON Investment, and DAYLI Partners.

“Our mission is to deliver degrader-antibody conjugate therapeutics that apply powerful degrader payloads with antibody-targeted precision to improve the treatment of cancer and other serious diseases,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “This investment supports the next stage of our growth as we prepare to advance our next therapeutic programs towards clinical evaluation, develop additional novel payloads, and continue to build platforms that can generate differentiated drug candidates across oncology and beyond. We appreciate the confidence of both new and existing investors who share our commitment to delivering meaningful innovation for patients.”

This investment supports the advancement of ORM-1153 and additional programs in Orum’s pipeline and continued refinement of the Company’s DAC platforms, including development of additional novel payload classes beyond GSPT1. It also supports the expansion of Orum’s scientific and operational infrastructure as the Company advances additional targeted DAC programs based on principles of selectivity, potency, and rational payload design. These efforts are foundational to Orum’s strategy to generate differentiated therapeutic DAC programs for oncology and other serious diseases.